More Data Back Guillain-Barré Risk With Janssen COVID S

Observed cases of Guillain-Barré syndrome after receipt of the Janssen shot were two to three times greater than background rates within 3-6 weeks of vaccination, new US surveillance data show.

Related Keywords

California , United States , Tennessee , Oakland , Vanderbilt University , Winston Abara , Kaiser Permanente , Nicola Klein , Vanderbilt Vaccine Research Program , Medscape Coronavirus Resource Center , Us Centers For Disease , Advisory Committee On Immunization Practices , Pfizer , Kaiser Permanente Vaccine Study Center , Astrazeneca , Vanderbilt University School Of Medicine , Coronavirus Resource , Vaccine Adverse Event Reporting System , Disease Control , Brighton Collaboration , Brighton Levels , Medscape Medical News , Vaccine Safety Datalink , Vanderbilt University School , Advisory Committee , Immunization Practices , Covid 19 Vaccine , Coronavirus Vaccine , Immunizations , Vaccination , Guillain Barre Syndrome , Adverse Effects Of Vaccines , Vaccine , Patient Safety , Coronavirus , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronavirus Oc43 , Cov Oc43 , Uman Coronavirus 229e , Cov 229e , Adenovirus , Adverse Effects , Side Effects , Clinical Research , Clinical Trials , Linical Studies , Medic ,